STOCK TITAN

SOPHiA GENETICS to Announce Financial Results for the Second Quarter of Fiscal 2023 on August 8, 2023

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

BOSTON and ROLLE, Switzerland, July 25, 2023 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced it will release its financial results for the second quarter of fiscal 2023 before U.S. markets open on Tuesday, August 8, 2023. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CEST.

The call will be webcast live on the SOPHiA GENETICS Investor Relations website. Additionally, a replay will be available on the website after its completion.

About SOPHiA GENETICS:
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native software company in the healthcare space dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers. 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-to-announce-financial-results-for-the-second-quarter-of-fiscal-2023-on-august-8-2023-301884596.html

SOURCE SOPHiA GENETICS

SOPHiA GENETICS SA Ordinary Shares

NASDAQ:SOPH

SOPH Rankings

SOPH Latest News

SOPH Stock Data

330.42M
46.15M
5.92%
49.96%
0.08%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Rolle

About SOPH

sophia genetics, world's largest clinical genomics community, brings together expertise in genetics, bioinformatics, machine learning and genomic privacy. based in switzerland, we are known for our high medical standards and swiss precision. sophia genetics offers health professionals who perform clinical genetic testing unparalleled bioinformatics analysis, quality assurance and secure banking of patient dna sequence data generated by ngs. the company helps clinical laboratories to reduce costs, overcome complexity, significantly improve the turnaround time for routine diagnosis and meet quality requirements related to the use of ngs in the clinic. our solution, the sophia ddm™ platform allows hospitals to better and faster diagnose patients using cutting edge ngs analytics algorithms and through knowledge sharing within the largest clinical genomics community in the world (+100 hospitals). the name « sophia » means wisdom in greek and it is the definition of our excellence based